S-1: Apimeds Pharmaceuticals US Files for IPO to Advance Bee Venom-Based Therapies

Apimeds Pharmaceuticals US, Inc. has filed an S-1 registration statement for an initial public offering to fund the clinical development of Apitox, a bee venom-based treatment for osteoarthritis and multiple sclerosis.

Summary

• Apimeds Pharmaceuticals US, Inc., a clinical-stage biopharmaceutical company, has filed an S-1 registration statement for an IPO.
• The company aims to raise capital to fund its Phase III clinical trial for Apitox, a purified bee venom-based treatment for knee osteoarthritis.
• Apitox is currently marketed in South Korea as Apitoxin for osteoarthritis.
• Apimeds US also plans to initiate non-registered corporate sponsorship studies to explore Apitox's potential in treating multiple sclerosis.
• The company intends to list its common stock on the NYSE American under the symbol APUS.
• Inscobee Inc., a South Korean corporation, currently holds approximately 88.81% of Apimeds US's common stock and will continue to hold a majority of the voting power after the offering.
• Apimeds US has generated no revenue from the sale or distribution of Apitox in the United States to date.

Sentiment

Score: 4

Explanation: The document presents a mixed sentiment. While it highlights the potential of Apitox and the market opportunity, it also acknowledges significant financial losses, risks, and dependence on related parties. The going concern warning and material weaknesses in internal controls are concerning.

Positives

• Apitox has already been approved in South Korea for treating pain and mobility in patients with osteoarthritis.
• A post-marketing safety study in South Korea showed no serious adverse events in over 3,000 patients treated with Apitoxin.
• The company has a royalty-bearing license from Apimeds Korea to utilize clinical development data and commercialize Apitox in the United States.
• Apimeds US believes there is a significant market opportunity in the United States for Apitox to enhance treatment of the lack of mobility and pain management symptoms associated with of OA and MS.
• The FDA provides 12-year market exclusivity at the time of approval of a BLA, with the potential for a six-month extension upon approval for pediatric use.

Negatives

• Apimeds US has not generated any revenue from the sale or distribution of Apitox in the United States.
• The company has incurred significant net losses since inception and anticipates that it will continue to incur substantial net losses for the foreseeable future and may never achieve profitability.
• The report of our independent registered public accounting firm included a going concern explanatory paragraph.
• We have identified material weaknesses in our internal control over financial reporting, and the failure to remediate these material weakness may adversely affect our business, investor confidence in our company, our financial results and the market value of our common stock.

Risks

• Clinical development has inherent risk in its process and our product candidate, Apitox, will be evaluated in a clinical environment for an indication which it has limited patient exposure which may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
• Even after this offering, we may require substantial additional funding to finance our operations.
• Our business is substantially dependent on our relationships with Apimeds Korea.
• We face significant competition, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidate we develop, our commercial opportunities will be negatively impacted.
• Our product candidate may cause undesirable side effects or have other properties that could halt its clinical development, prevent its regulatory approval, limit its commercial potential or result in significant negative consequences.
• We rely on principally on trade secrets and other forms of non-patent intellectual property protection, which are difficult to protect.

Future Outlook

Apimeds US intends to use the net proceeds from this offering to fund its Phase III clinical trial in knee OA, to initiate at least one non-registered company sponsored trials in MS, manufacturing costs, and any remaining amounts to fund working capital and general corporate purposes.

Industry Context

The announcement comes amid growing interest in alternative therapies for chronic diseases like osteoarthritis and multiple sclerosis, where existing treatments often have limitations or undesirable side effects. The company is positioning Apitox as a potential treatment alternative for certain symptoms of MS.

Comparison to Industry Standards

• The OA therapeutics market size in the United States accounted for $8.28 billion in 2022 and it is expected to hit around $20.24 billion by 2032, expanding at a compounded annual growth rate, or CAGR, of 9.4% from 2023 to 2032, according to Precedence Research.
• According to Pharmaceutical Technology the MS market size in the United States accounted for $ 10.73 billion in 2022 and is expected to hit $ 24.4 billion by 2030, expanding at a CAGR of 10.32%.

Related Party Transactions

• The company is substantially dependent on its relationships with Apimeds Korea.
• We are dependent on a license from our principal shareholder, Apimeds Korea, to continue our clinical trials and development of Apitox.
• There may be conflicts of interest amongst our directors and officers and Apimeds Korea.
• The Company is reliant on its key supplier.

Stakeholder Impact

• An investment in our securities involves a high degree of risk and could result in a loss of your entire investment.
• Raising additional capital may cause dilution to our stockholders, including investors in this offering, restrict our operations or require us to relinquish rights to one or more of our technologies.

Next Steps

• Initiate an additional Phase III trial in advanced knee OA, focusing on efficacy of a shorter-term treatment of patients who are eligible for knee replacement surgery.
• Initiate multiple company sponsored trials in MS to determine the best path to clinical Phase III success.
• Pursue potential collaboration arrangements and out-licensing opportunities.
• Seek non-dilutive funding and grant awards to support our clinical research and product candidate development.

Key Dates

Keywords

Apitox, Apimeds Pharmaceuticals US, osteoarthritis, multiple sclerosis, bee venom, clinical trial, biopharmaceutical, IPO, Apitoxin, Inscobee